Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Summary

The aim of this study is to compare the efficacy of Toripalimab Combined with GP Regimen Chemotherapy Versus GP Regimen Chemotherapy for Primary Metastatic NPC.

Conditions

• Nasopharyngeal Carcinoma

Interventions

DRUG

Toripalimab

PD-1 inhibitor

RADIATION

IMRT to the nasopharynx and neck

IMRT to the nasopharynx and neck

DRUG

Gemcitabine and Cisplatin Chemotherapy

Systemic chemotherapy

DRUG

Adjuvant chemotherapy with Capecitabine

Adjuvant chemotherapy after radiation

Sponsors & Collaborators

• Fudan University Eye and ENT Hospital

  collaborator UNKNOWN

• Anhui Provincial Hospital

  collaborator OTHER_GOV

• Sir Run Run Shaw Hospital

  collaborator OTHER

• Hangzhou Cancer Hospital

  collaborator OTHER

• Ningbo Medical Center Lihuili Hospital

  collaborator OTHER_GOV

• The First People's Hospital of Changzhou

  collaborator OTHER

• Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

  collaborator OTHER

• Affiliated Cancer Hospital & Institute of Guangzhou Medical University

  collaborator OTHER

• Nanfang Hospital, Southern Medical University

  collaborator OTHER

• Shenzhen People's Hospital

  collaborator OTHER

• First Affiliated Hospital of Xi'anJiaotong Univerisity

  collaborator UNKNOWN

• Guangzhou Panyu Central Hospital

  collaborator OTHER

• Fujian Cancer Hospital

  collaborator OTHER_GOV

• Fudan University

  lead OTHER

Principal Investigators

• Chaosu Hu, M.D. · Fudan University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-11-01

Primary Completion

2025-12-31

Completion

2026-12-31

Countries

• China

Study Locations